US FDA warns J&J over clinical trial violations for ceftobiprole
This article was originally published in Scrip
Executive Summary
The US FDA has cited Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) for "objectionable conditions" in two clinical trials for the investigational antibiotic ceftobiprole.